Elsevier

Blood Reviews

Volume 3, Issue 3, September 1989, Pages 152-161
Blood Reviews

Interleukin-1 and hematopoiesis

https://doi.org/10.1016/0268-960X(89)90012-XGet rights and content

Abstract

Interleukin-1α and interleukin-1β are 17.5kDa peptides which exert a wide variety of biological activities. Both forms of interleukin bind to a common 60–70kDa receptor expressed by most somatic cells. One major effect of interleukin-1 is to induce the expression of other genes, including genes for other interleukins (IL-6), colony stimulating factors (GM-CSF and G-CSF) and growth factors (PDGFA) and adhesion proteins (ELAM-1, ICAM-1). In vitro, cells of the hematopoietic stroma including thymic epithelium, endothelial cells, fibroblasts, T-lymphocytes, and macrophages, are all capable of responding to interleukin-1 by expressing most of these IL-1 inducible genes. Accordingly, because interleukin-1 has no direct effect on hematopoietic progenitor cells, its major effect on hematopoiesis is to regulate the expression of hematopoietic growth factor genes by other cells. The mechanism by which interleukin-1 induces gene expression is to first induce mRNA accumulation which accounts for an increase in translation of the mRNA. The accumulation of RNA, interestingly, does not result from increased transcription of these genes but by the stabilization of the mRNA. Ordinarily, the hematopoietic growth factor gene transcripts have a very short half-life but in an interleukin-1 induced cell, the half-life of these transcripts is markedly prolonged (> 24 h). This particular effect of IL-1 on transcript stability likely accounts for virtually all of the hematopoietic activities of interleukin-1 including: (1) induction of growth factors; (2) synergy with other factors; (3) priming; and (4) auto-induction. Three clinical models of hematopoiesis are presented which suggest that the interleukin-1 CSF network is operative in vivo. The ability of interleukin-1 to induce the expression of hematopoietic growth factor genes as well as genes whose products regulate cellular function and traffic suggest that interleukin-1 is an essential molecular master switch for a number of cellular responses occurring in organisms facing the vicissitudes of their environment.

References (118)

  • D Ridgway et al.

    Granulocyte macrophage colony stimulating activity production by cultured human thymic non-lymphoid cells is regulated by endogenous interleukin-1

    Blood

    (1988)
  • A Mauviel et al.

    Interleukin-1 α and β induce interleukin-1 β gene expression in human dermal fibroblasts

    Biochemical Biophysical Research Communications

    (1988)
  • T Nishida et al.

    The transcription of the interleukin 1β gene is induced with PMA and inhibited with dexamethasone in U937 cells

    Biochemical and Biophysical Research Communications

    (1988)
  • S.D. Sisson et al.

    Production of interleukin-1α, interleukin-1β and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor

    Blood

    (1988)
  • M Hurme et al.

    Interleukin-4 inhibits interleukin-1 synthesis by a posttranscriptional mechanism

    Biochemical and Biophysical Research Communications

    (1988)
  • M Turner et al.

    Posttranscriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1

    Biochemical and Biophysical Research Communications

    (1988)
  • M Dukovich et al.

    Stimulation of fibroblast proliferation and prostaglandin production by purified recombinant murine IL-1

    Clinical Immunology and Immunopathology

    (1986)
  • F Bussolino et al.

    Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha

    Journal of Biological Chemistry

    (1988)
  • G Beck et al.

    Characterization of interleukin-1 activity in tunicates

    Comparative Biochemistry and Physiology

    (1989)
  • C.A. Sieff et al.

    Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells

    Blood

    (1988)
  • A Barberis et al.

    Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter

    Cell

    (1987)
  • GM Segal et al.

    The erythroid burst promoting activity produced by interleukin-1 stimulated endothelial cells is granulocyte macrophage colony stimulating factor

    Blood

    (1988)
  • W.E. Fibbe et al.

    Interleukin 1 (22K factor) induces release of granulocyte-macrophage colony-stimulating activity from human mononuclear phagocytes

    Blood

    (1986)
  • E McCall et al.

    Monocyte-derived recruiting activity. Kinetics of production and effects of endotoxin

    Blood

    (1985)
  • GC Bagby et al.

    A monokine regulates colony-stimulating activity production by vascular endothelial cells

    Blood

    (1983)
  • G Shaw et al.

    A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation

    Cell

    (1986)
  • Kruys et al.

    Identification of a translation inhibitory element (TIE) in the 3′ untranslated region of the human interferon-β mRNA

    Gene

    (1988)
  • D Lindholm et al.

    Interleukin 1 increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts

    Journal of Biological Chemistry

    (1988)
  • E.R. Stanley et al.

    Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1

    Cell

    (1986)
  • IK McNiece et al.

    Studies on the myeloid synergistic factor from 5637: comparison with interleukin-1 alpha

    Blood

    (1989)
  • K Ikebuchi et al.

    Synergistic factors for stem cell proliferation: Further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factor

    Blood

    (1988)
  • D.E. Williams et al.

    Interleukin-1α enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony-stimulating factors

    Blood

    (1988)
  • R.E. Donahue et al.

    Stimulation of hematopoiesis in primates by continuous infusion of recombinant human GM-CSF

    Nature

    (1986)
  • G Morstyn et al.

    Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

    Lancet

    (1988)
  • S.J. Brandt et al.

    Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation

    New England Journal of Medicine

    (1988)
  • J.L. Gabrilove et al.

    Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

    New England Journal of Medicine

    (1988)
  • GM Segal et al.

    Interleukin 1 stimulates endothelial cells to release multilineage human colony-stimulating activity

    Journal of Immunology

    (1987)
  • GC Bagby

    Production of multilineage growth factors by hematopoietic stromal cells: an intercellular regulatory network involving mononuclear phagocytes and interleukin-1

    Blood Cells

    (1987)
  • VC Broudy et al.

    Tumor necrosis factor type α stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor

  • GM Segal et al.

    Vascular endothelial cells and hematopoietic regulation

    International Journal of Cell Cloning

    (1988)
  • D Simmons et al.

    ICAM, an adhesion ligand of LFA-1, is homologous to the neutral cell adhesion molecule NCAM

    Nature

    (1988)
  • A.W. Boyd et al.

    Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms

  • M.P. Bevilacqua et al.

    Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins

    Science

    (1989)
  • G.L. Howells et al.

    Interleukin 1 (IL-1) and tumour necrosis factor synergise in the induction of IL-1 synthesis by human vascular endothelial cells

    Immunology Letters

    (1988)
  • S.N. Vogel et al.

    Recombinant interleukin-1α and recombinant tumor necrosis factor α synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes

    Infection and Immunity

    (1988)
  • P.E. Auron et al.

    Nucleotide sequence of human monocyte interleukin 1β precursor cDNA

  • B.D. Clark et al.

    Genomic sequence for human prointerleukin 1 beta: possible evolution from a reverse transcribed prointerleukin 1 alpha gene

    Nucleic Acids Research

    (1986)
  • Y Furutani et al.

    Complete nucleotide sequence of the gene for human interleukin 1α

    Nucleic Acids Research

    (1986)
  • U Gubler et al.

    Recombinant human interleukin 1: purification and biological characterization

    Journal of Immunology

    (1986)
  • C.J. March et al.

    Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs

    Nature

    (1985)
  • Cited by (92)

    • The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators

      2018, Cytokine and Growth Factor Reviews
      Citation Excerpt :

      Whereas GATA2 expression is tightly regulated during hematopoiesis, overexpression of GATA2 is frequently observed in AML patients where it is linked to poor prognosis [40]. Thus, enhanced IL-1-induced p38-signaling, as observed in IL-1β-sensitive AML patients, may result in the dysregulation of GATA2 activation in the context of leukemic cell proliferation and thereby be a crucial factor in AML disease progression [17,39,41–43] (Fig. 1). Because normal hematopoietic stem cells (HSCs) experience severe impairment of self-renewal capacity and even undergo growth suppression upon IL-1β exposure, whereas IL-1β acts as a potent survival factor for leukemic cells [11], IL-1β and components of the IL-1β signaling pathway may be promising targets for future therapeutic approaches.

    • Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications

      2017, Blood Reviews
      Citation Excerpt :

      This review presents the pathogenic role of dysregulated IL-1β in patients of hematological malignancies, its promising therapeutic value in preclinical models, and its potential contribution linking to second disease and complications based on lessons learned from other systemic inflammatory diseases. IL-1β is mainly produced by myeloid cells [10,11]. It is synthesized as an inactive form (Fig. 1A), pro-IL-1β that is activated intracellularly by caspase 1 [8,11].

    • Psychological and cytokine changes in children and adolescents undergoing hematopoietic stem cell transplantation

      2007, European Neuropsychopharmacology
      Citation Excerpt :

      Various confounding factors may affect cytokine production and activity. These factors include stress (Raz, 1997), steroid treatment (Bagby, 1989; Oppenhiem and Ruscetti, 2001), Granulocyte Colony-Stimulating Factor (G-CSF) administration (Oppenhiem and Ruscetti, 2001; Tayebi et al., 2001; Vilcek, 1998), and the use of antibiotics. The diagnoses of our subjects are heterogeneous leading to different protocols and intervals of time in the transplantation process.

    • Monocyte-derived CXCL7 peptides in the marrow microenvironment

      2006, Blood
      Citation Excerpt :

      In vitro, the monocytes, which arise from the hematopoietic stem cell, can form up to 40% of total cells in LTCs despite serial passages.7 Monocytes/macrophages are known to secrete large quantities of several cytokines, including IL-1, IL-6, G-CSF, TNF, PDGF, TGF-β, and M-CSF, all of which can affect both stromal cells and hematopoietic cells.8-13 Increasing proportions of macrophages in primary LTCs are associated with decreasing numbers of hematopoietic progenitors.14,15

    View all citing articles on Scopus
    View full text